560 related articles for article (PubMed ID: 32896105)
1. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
Margulis V; Puligandla M; Trabulsi EJ; Plimack ER; Kessler ER; Matin SF; Godoy G; Alva A; Hahn NM; Carducci MA; Hoffman-Censits J;
J Urol; 2020 Apr; 203(4):690-698. PubMed ID: 31702432
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
6. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.
Almassi N; Gao T; Lee B; Stein RJ; Haber GP; Ornstein MC; Rini BI; Gilligan TD; Garcia JA; Stephenson AJ; Grivas P
Clin Genitourin Cancer; 2018 Dec; 16(6):e1237-e1242. PubMed ID: 30217764
[TBL] [Abstract][Full Text] [Related]
7. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
10. Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage.
Chen CS; Lin CY; Wang CL; Wang SS; Li JR; Yang CK; Cheng CL; Chiu KY; Yang SF
Urol Oncol; 2021 Feb; 39(2):132.e13-132.e26. PubMed ID: 32900630
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
12. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes in Neoadjuvant Chemotherapy for High-grade Upper Tract Urothelial Carcinoma: A Nationally Representative Analysis.
Khan AI; Taylor BL; Al Hussein Al Awamlh B; Posada Calderon L; Fainberg J; Elahjji R; Shoag J; Scherr DS
Urology; 2020 Dec; 146():158-167. PubMed ID: 32896584
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion.
Godfrey MS; Badalato GM; Hruby GW; Razmjoo M; McKiernan JM
BJU Int; 2012 Sep; 110(6):798-803. PubMed ID: 22313599
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.
Necchi A; Lo Vullo S; Mariani L; Moschini M; Hendricksen K; Rink M; Sosnowski R; Dobruch J; Raman JD; Wood CG; Margulis V; Roupret M; Briganti A; Montorsi F; Xylinas E; Shariat SF;
BJU Int; 2018 Feb; 121(2):252-259. PubMed ID: 28940605
[TBL] [Abstract][Full Text] [Related]
17. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Song W; Jeong JY; Jeon HG; Seo SI; Jeon SS; Choi HY; Lee HM; Sung HH
Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
[TBL] [Abstract][Full Text] [Related]
18. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy.
Kitamura H; Igarashi M; Tanaka T; Shindo T; Masumori N; Tamakawa M; Kawaai Y; Tsukamoto T
Jpn J Clin Oncol; 2012 Dec; 42(12):1192-6. PubMed ID: 23077244
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
